Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing
about
Plant-derived vaccines: a look back at the highlights and a view to the challenges on the road ahead.Immune Evasion Strategies during Chronic Hepatitis B and C Virus InfectionNonresponse to hepatitis B vaccines and the kinetics of anti-HBs production.Perinatal transmission of hepatitis B virus and its prevention.
P2860
Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing
description
im September 1994 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 1994
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1994
@uk
name
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@en
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@nl
type
label
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@en
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@nl
prefLabel
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@en
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@nl
P2093
P1433
P1476
Safety and efficacy of a recom ...... se 1, 2 and 3 clinical testing
@en
P2093
P304
P356
10.1016/0264-410X(94)90178-3
P407
P577
1994-09-01T00:00:00Z